Skinny labels dont announce themselves. They arrivequietly, as competitors line up authorized generics of your products future. And by the time most teams notice, the window to shape strategy is already closing.
The most important clue often isnt in th…

Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…

Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…

Paragraph IV isnt broken. Its being outmaneuveredpredictably.
If youve spent the last few years building (or defending) a Paragraph IV strategy, youve probably seen the same pattern play out: the certainties you rely ongeneric timing, litigation levera…

The First-Filer Trap: Why 180-Day Exclusivity Fails Without a Supply-Chain Moat
Generic drug strategy has a myth problem.
Executives still talk about the 180-day exclusivity as if its a finish linesomething you win once youre first. But in practice, th…

Most companies chase the same thing: blockbuster drugs with massive revenue potential. But the smart play in 2026and beyondmay be almost the opposite: stop chasing unloved orphan patents with blockbuster assumptions and start monetizing them with a dis…

Your regulatory team doesnt have a patent problem. It has a timing problem.
Thats the uncomfortable truth hiding behind most late-stage surprises in pharma. A regulator-facing CMC package can be flawless, a submission can be perfectly compliant, and an…

Big pharma doesnt lose its edge because R&D gets slower.
It loses its edge because R&D gets blindsided.
That late pivot momentwhen a promising program suddenly hits patent/market access constraints, generic entry timelines, or unexpected exclus…

Ever notice how people talk about biosimilars like the hard part is proving theyre the same?
That partbioequivalenceis undeniably important. But if youre building a biologics strategy, you quickly learn the truth: bioequivalence is often the easy part….

In pharma, doing less can sometimes look like geniusuntil you realize its a bet against the calendar.
Drugmakers have spent the last decade optimizing everything they can measure: launch sequencing, manufacturing capacity, pricing strategy, and pipelin…